Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice

Eiji Kikuchi, Yutaka Horiguchi, Jun Nakashima, Kenji Kuroda, Mototsugu Oya, Takashi Ohigashi, Nozomu Takahashi, Yutaka Shima, Kazuo Umezawa, Masaru Murai

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

We have synthesized and explored the feasibility of using a novel nuclear factor (NF) κB inhibitor, a dehydroxymethylepoxyquinomicin designated as DHMEQ, against prostate cancer. The activity of NFκB, evaluated by transient transfection of a luciferase reporter DNA containing a specific binding sequence for NFκB, was inhibited by DHMEQ in three human hormone-refractory prostate cancer cell lines, DU145, JCA-1, and PC-3. Statistically significant growth inhibition was achieved by 20 μg/ml of DHMEQ, and marked levels of apoptosis were induced 48 h after DHMEQ administration in vitro. Electrophoretic mobility shift assay showed that DHMEQ completely inhibited NFκB DNA binding activity in JCA-1 cells. Furthermore, i.p. administrations of DHMEQ significantly inhibited pre-established JCA-1 s.c. tumor growth in nude mice without any side effects. Our result indicates the possibility of using a novel NFκB activation inhibitor, DHMEQ, as a new treatment strategy against hormone-refractory prostate cancer.

Original languageEnglish
Pages (from-to)107-110
Number of pages4
JournalCancer Research
Volume63
Issue number1
Publication statusPublished - 2003 Jan 1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice'. Together they form a unique fingerprint.

  • Cite this

    Kikuchi, E., Horiguchi, Y., Nakashima, J., Kuroda, K., Oya, M., Ohigashi, T., Takahashi, N., Shima, Y., Umezawa, K., & Murai, M. (2003). Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Research, 63(1), 107-110.